In this context, the CXCR4 inhibitors, which antagonize the effects of the CXCR4 ligand SDF-1α secreted by CAFs preventing the development of breast cancer cell metastasis, have received much interest [115]. This evidence concerns the gene CXCL12 and breast carcinoma.